Kitara Capital
Indian drug maker Vivimed gets $25.8m from private equity
NYLIM Jacob Ballas India Fund and Kitara Capital have committed INR1.27 billion ($25.8 million) to Indian pharmaceutical firm Vivimed Labs.
NYLIM Jacob Ballas India Fund and Kitara Capital have committed INR1.27 billion ($25.8 million) to Indian pharmaceutical firm Vivimed Labs.